Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Axis-Shield, an in-vitro diagnostics company, has signed an agreement with Abbott to develop and manufacture its proprietary Active-B12 assay to run on Abbott's Architect family of automated immunoassay analyzers.
Subscribe to our email newsletter
According to Axis-Shield, Active-B12 is a more efficient method for detection of vitamin B12 deficiency compared to the measurement of total B12 in the blood, as it measures only the biologically available component of absorbed B12, present as holo-transcobalamin (around 20-30% of the total).
Ian Gilham, Axis-Shield CEO, said: “We are pleased to have signed this agreement with Abbott as the Architect platforms are designed to address the changing needs of laboratories of all sizes and represent the systems of the future. The automated technology provides workflow efficiencies and allows laboratories to integrate immunoassay and clinical chemistry testing onto one platform.
“We look forward to the opportunity to grow the market for this important test, and initially expect the assay will be used to resolve the 30% or so of total B12 results which are discrepant and difficult to determine, and ultimately to replace total B12 determinations completely.”